About AEON Biopharma, Inc.
http://www.aeonbiopharma.comAEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019.
CEO
Robert Bancroft
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-02-26 | Reverse | 1:72 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
ATALAYA CAPITAL MANAGEMENT LP
Shares:3.67M
Value:$4.02M
BLACKROCK INC.
Shares:272.32K
Value:$298.19K
Summary
Showing Top 2 of 2
About AEON Biopharma, Inc.
http://www.aeonbiopharma.comAEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $2.49M ▼ | $-4.54M ▲ | 0% | $-0.39 ▲ | $-2.51M ▲ |
| Q2-2025 | $0 | $4.34M ▲ | $-6.64M ▼ | 0% | $-0.6 ▼ | $-4.3M ▼ |
| Q1-2025 | $0 | $462K ▼ | $9.1M ▲ | 0% | $2.28 ▼ | $-3.93M ▲ |
| Q4-2024 | $0 | $2.32M ▼ | $2.08M ▲ | 0% | $3.76 ▲ | $-5.64M ▼ |
| Q3-2024 | $0 | $4.02M | $-6.17M | 0% | $-11.24 | $-3.99M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $5.93M ▼ | $8.73M ▼ | $28.61M ▲ | $-19.87M ▼ |
| Q2-2025 | $8.44M ▼ | $11.66M ▼ | $27.51M ▲ | $-15.85M ▼ |
| Q1-2025 | $10.45M ▲ | $13.8M ▲ | $25.12M ▼ | $-11.32M ▲ |
| Q4-2024 | $13K ▼ | $3.14M ▼ | $31.71M ▼ | $-28.57M ▲ |
| Q3-2024 | $537K | $4M | $36.09M | $-32.09M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-4.54M ▲ | $-2.6M ▼ | $0 | $84K | $-2.51M ▼ | $-2.6M ▼ |
| Q2-2025 | $-6.64M ▼ | $-2.09M ▲ | $0 ▲ | $84K ▼ | $-2.01M ▼ | $-2.09M ▲ |
| Q1-2025 | $9.1M ▲ | $-7.91M ▼ | $-4K ▼ | $18.35M ▲ | $10.43M ▲ | $-7.91M ▼ |
| Q4-2024 | $2.08M ▲ | $-621K ▲ | $0 | $97K ▲ | $-524K ▲ | $-621K ▲ |
| Q3-2024 | $-6.17M | $-2.96M | $0 | $50K | $-2.9M | $-2.96M |
CEO
Robert Bancroft
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-02-26 | Reverse | 1:72 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
ATALAYA CAPITAL MANAGEMENT LP
Shares:3.67M
Value:$4.02M
BLACKROCK INC.
Shares:272.32K
Value:$298.19K
Summary
Showing Top 2 of 2